<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>MHC-I loss &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/mhc-i-loss/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Wed, 28 Oct 2026 00:45:22 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.1.3</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>MHC-I loss &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>CD4 T Cell Help Powers Immunotherapy Response in Tumors Lacking MHC-I</title>
		<link>https://bioengineer.org/cd4-t-cell-help-powers-immunotherapy-response-in-tumors-lacking-mhc-i/</link>
		
		<dc:creator><![CDATA[]]></dc:creator>
		<pubDate>Wed, 28 Oct 2026 00:45:22 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[anti-CTLA4]]></category>
		<category><![CDATA[anti-PD1]]></category>
		<category><![CDATA[CD4+ T cells]]></category>
		<category><![CDATA[CD40 signaling]]></category>
		<category><![CDATA[CD8+ T cells]]></category>
		<category><![CDATA[checkpoint blockade]]></category>
		<category><![CDATA[Colorectal cancer]]></category>
		<category><![CDATA[immunotherapy]]></category>
		<category><![CDATA[MHC-I loss]]></category>
		<category><![CDATA[mismatch repair deficiency]]></category>
		<category><![CDATA[mouse models]]></category>
		<category><![CDATA[Tumor Immune Evasion]]></category>
		<guid isPermaLink="false">https://bioengineer.org/?p=465144</guid>

					<description><![CDATA[Mouse experiments show that CD4+ T cells license CD8+ T cells through CD40 signaling, enabling combination immunotherapy to eliminate mismatch repair-deficient colorectal tumors that have lost MHC-I expression.]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">465144</post-id>	</item>
	</channel>
</rss>
